CVS Health Analysis 2026 — 190% Payout, but the Dividend Is Covered Twice

Published: July 1, 2026  ·  Prices as of July 1, 2026 (FMP /stable)  ·  Not investment advice. Marco holds CVS Health in his own portfolio — he is not neutral.

Related: Pharma Investing Guide 2026 — how to analyze healthcare dividend stocks beyond the surface numbers.

Glossary: Cashflow Coverage explained — the most important dividend safety metric: how well does free cash flow cover the dividend?

Hub: Best High-Yield Dividend Stocks 2026 — top stocks paying 5–15% dividends in healthcare, shipping, mining, and energy.

The Business Model — Not a Drugstore, a Healthcare Colossus

Most investors still think of CVS as the pharmacy around the corner. That is only one-third of the story. CVS is today a vertically integrated healthcare company — the only US firm that holds all three links of the healthcare chain under one roof.

The integration is simultaneously the moat and the political target. As insurer, Aetna collects premiums. As PBM, Caremark captures the drug distribution margin. In the pharmacy, prescriptions are dispensed. A closed loop — which is exactly why Washington has CVS in its sights from both parties.

The cautionary tale hanging over everything: Walgreens. The large pharmacy competitor was taken private in 2025 — Sycamore Partners bought the company for approximately $10 billion, and the dividend had already been cut beforehand. Pure pharmacy retail as a public equity story is finished. CVS survives only because it is more than just a pharmacy. If the other two pillars falter, the same fate is within reach.

The Honest Payout Resolution — GAAP vs. Free Cash Flow

This is the core of why most people misread this stock. On reported GAAP earnings of $1.39 per share, CVS pays $2.66 in dividends — roughly 190%. On paper, the company is burning nearly twice its earnings to fund the dividend. That sounds like an imminent cut.

But that reported earnings figure is impaired — by a $5.7 billion goodwill write-down on Oak Street Health in 2025. A goodwill impairment. And a goodwill impairment does not cost a single dollar in cash. It is pure accounting. The books are written down, but no money leaves the building.

The honest number: CVS generated $7.8 billion in free cash flow. Of that, approximately $3.4 billion went to the dividend. That is 44% — the real cash covers the dividend roughly twice.

That said — CVS is not a dividend aristocrat anymore. The annual increase streak broke in 2018 after the Aetna acquisition. For six years, the dividend was frozen to protect the credit rating while paying down debt. The first increase came in 2024, from $0.605 to $0.665 per quarter, approximately 10%. Since then, it has been flat again. If you read "39 years of dividend history" somewhere — do not confuse continuity with growth. They never cut, but they froze for six years.

My view: near-term cut risk is low. Free cash flow covers the dividend twice and management has been explicit about maintaining the dividend at the current level while reducing leverage. But the upside from meaningful increases is capped until the balance sheet improves significantly.

Glossary: Free Cash Flow explained — why FCF is more important than earnings for dividend investors, and how to calculate it from annual reports.

Glossary: Dividend Safety explained — the 5 metrics that predict dividend cuts before they happen.

The Balance Sheet — The Heavy Side, Unvarnished

The balance sheet is genuinely heavy. Net debt rose to approximately $85 billion in 2025. On top of that sits a goodwill balance of roughly $85.5 billion — the premium paid for Aetna, Oak Street, and Signify Health. The $5.7 billion impairment was an admission that Oak Street was bought too expensively. Further impairments are possible.

On leverage: the raw GAAP Net Debt/EBITDA stands at roughly 6.5, but that is distorted upward by the same impairment compressing reported earnings. CVS calculates on an adjusted basis at approximately 4.3 (improved from 4.7 the prior quarter). The target is "low 3x." Both numbers are legitimate; they measure different things.

Interest coverage is thin at roughly 1.9x — operating earnings cover interest expense just under twice. At higher refinancing rates, that leaves limited cushion.

Q1 2026 — The Turnaround Is Now In the Numbers

The Q1 2026 numbers were strong. CVS reported adjusted EPS of $2.57 — versus consensus estimates of $2.21, a beat of approximately 16%. Revenue: $100 billion in a single quarter, up 6% year over year.

The critical data point: Aetna's medical benefit ratio — the number that exploded in 2024 and triggered the whole collapse — fell from approximately 87% to 84.6%. Operating income in the insurance segment rose more than 50%. The costs are coming back under control. That is exactly the healing the bulls were betting on.

Management was confident enough to raise full-year guidance from $7.00–7.20 to $7.30–7.50 per share. A company that raises guidance after two years of constant cuts — that is the real story of 2026.

Valuation — Cheap for a Reason, but Not Unreasonable

On adjusted EPS of $6.75, the P/E stands at roughly 15x. For a defensive healthcare company with a vertically integrated model that no peer can fully replicate, that is inexpensive. FCF yield sits at approximately 6%.

My range — explicitly not a price target: if Aetna margins normalize and the market pays 16–17x adjusted earnings, the fair value band is roughly $108 to $125. If margin pressure returns or another impairment hits, $75 to $85 is also a plausible scenario. At $103, the market is pricing exactly what is happening: turnaround underway, but not complete. No price guarantee, no investment advice.

My Take — Portfolio Context

CVS is a cash flow machine in turnaround mode. Free cash flow covers the dividend twice. The integrated model — insurer, PBM, pharmacy — has no real twin. Nobody else holds all three links of the chain under one roof.

But it is not a high-yield set-and-forget. A 2.6% yield, six years of frozen increases, a heavy balance sheet at 4.3x leverage with goodwill larger than half the company. And after a rally from $58.50 to $103, it is no longer a no-brainer at the lows.

My take: I hold CVS and would add at weakness — say, below $85. The same logic applies here as with cyclically beaten-down businesses that generate real cash: hold and add on weakness. The balance sheet remains the sword of Damocles. But the cash flow is real. The easy trade — buying at the lows — is over for 2026.

Glossary: Cashflow Coverage — the most important dividend safety metric →

Glossary: Dividend Safety — 5 metrics that predict cuts before they happen →

Marco Bozem

Investor & Analyst | Hard Assets, Dividends, Healthcare | MB Capital Strategies

Marco analyzes dividend stocks with a focus on cash flow and fundamentals. He holds positions in companies he covers, including CVS Health. All analysis is based on public financial reports and personal assessment. Not financial advice.

About Marco · YouTube · LinkedIn

Related: Best High-Yield Dividend Stocks 2026 — Full Overview · Pharma Investing Guide 2026